Abstract:Objective:Objective to compare and analyze the clinical efficacy, safety and effective dose of gabapentin and topiramate combined with venlafaxine in the treatment of chronic migraine patients with generalized anxiety disorder. Methods:According to the random number table method, 142 patients with chronic migraine were included in the gabapentin plus venlafaxine group (71 cases in the treatment group) and topiramate plus venlafaxine group (71 cases in the control group), all of which were treated for 6 months. Respectively to assess patients of two groups before and after 3, 6 months treatment headache days per month, migraine headache severity visual analogue scale (VAS), migraine specific quality of life questionnaire (MSQ V2.1), determination of headache impact - 6 (HIT - 6), Pittsburgh sleep quality index (PSQI), Hamilton anxiety scale (HAMA) score and adverse drug reactions. Results:After 6 months of treatment, the number of headache days, VAS, HIT-6, PSQI scores and MSQ V2.1 total scores in both groups all decreased, and the number of headache days in the treatment group decreased more significantly (P < 0.05). Gabapentin oral dose 1.2 g/d accounted for 72.00% of the effective patients, topiramate oral dose 100 mg/d accounted for 64.15% of the effective patients, and venlafaxine oral dose 75mg/d accounted for 58.68% of the effective patients. The incidence of adverse drug reactions in both groups was low (P > 0.05). Conclusion:Gabapentin (1.2 g/d) or topiramate (100 mg/d) combined with venlafaxine (75 mg/d) can significantly reduce the number of migraine days in patients with chronic migraine with generalized anxiety disorder, reduce the pain level of migraine patients, improve sleep, improve quality of life, and reduce adverse reactions. Gabapentin combined with Venlafaxine was associated with a greater reduction in the number of days with chronic migraine attacks.
